RD Biomed is an innovator in healthcare product
development, with a focus on gastroenterology
RD Biomed’s flagship product is our diagnostic device Peptest – an immunological in-vitro diagnostic medical device that can rapidly detect the gastric enzyme pepsin in saliva/sputum and exhaled breath condensate samples.
The presence of pepsin in saliva or exhaled breath is an indicator of gastro-oesophageal reflux disease (GORD) which affects 20-30% of all adults or Larygopharyngeal Reflux (LPR) which is often referred to as “silent reflux”
RD Biomed’s products have been routinely used with patients in global gastroenterology, ENT, chest and respiratory clinics and have a wide use in paediatrics.
RD Biomed founder and director Professor Peter Dettmar is the author or co-author of more than 530 journal papers, abstracts and book chapters on gastro-intestinal matters.
RD Biomed has achieved ISO 13485: 2016 certification – the internationally agreed standard specific to the medical devices industry.
“Peptest is the first test available that will help us to gain a much clearer understanding of the entity that we call ‘extraoesophageal reflux’. Once Peptest is used much more extensively, we will have treatments available that can change the course of the disease.”
“Peptest is fantastic to use because its simplicity means I do not have to refer my patient to secondary care. Secondary care would incur the money and expense of their referral, added to the expense of the endoscope procedure, whereas Peptest is a fraction of this cost”
RDBiomed Limited – a private limited company registered in England and Wales with number 06979218.
Daisy Building (2nd Floor)
Castle Hill Hospital
HU16 5JQ, UK
VAT Number: GB 990 1918 96